Open Access
Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection
Thomas R Lane
1
,
Christopher Massey
2
,
Jason E. Comer
3
,
Manu Anantpadma
4
,
Joel S Freundlich
5
,
Robert A Davey
4
,
Peter B Madrid
6
,
1
Collaborations Pharmaceuticals, Inc., Raleigh, NC, United States of America
|
6
SRI International, Menlo Park, CA, United States of America
|
Publication type: Journal Article
Publication date: 2019-11-21
scimago Q1
wos Q1
SJR: 1.370
CiteScore: 7.0
Impact factor: 3.4
ISSN: 19352727, 19352735
PubMed ID:
31751347
Infectious Diseases
Public Health, Environmental and Occupational Health
Abstract
Recent outbreaks of the Ebola virus (EBOV) have focused attention on the dire need for antivirals to treat these patients. We identified pyronaridine tetraphosphate as a potential candidate as it is an approved drug in the European Union which is currently used in combination with artesunate as a treatment for malaria (EC50 between 420 nM—1.14 μM against EBOV in HeLa cells). Range-finding studies in mice directed us to a single 75 mg/kg i.p. dose 1 hr after infection which resulted in 100% survival and statistically significantly reduced viremia at study day 3 from a lethal challenge with mouse-adapted EBOV (maEBOV). Further, an EBOV window study suggested we could dose pyronaridine 2 or 24 hrs post-exposure to result in similar efficacy. Analysis of cytokine and chemokine panels suggests that pyronaridine may act as an immunomodulator during an EBOV infection. Our studies with pyronaridine clearly demonstrate potential utility for its repurposing as an antiviral against EBOV and merits further study in larger animal models with the added benefit of already being used as a treatment against malaria.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
ACS Omega
3 publications, 6.82%
|
|
|
Journal of Chemical Information and Modeling
3 publications, 6.82%
|
|
|
ACS Infectious Diseases
2 publications, 4.55%
|
|
|
Frontiers in Pharmacology
2 publications, 4.55%
|
|
|
Bioorganic and Medicinal Chemistry
2 publications, 4.55%
|
|
|
Drug Discovery Today
2 publications, 4.55%
|
|
|
ACS Medicinal Chemistry Letters
1 publication, 2.27%
|
|
|
Molecular Pharmacology
1 publication, 2.27%
|
|
|
Cells
1 publication, 2.27%
|
|
|
BMC Infectious Diseases
1 publication, 2.27%
|
|
|
Pharmaceutical Research
1 publication, 2.27%
|
|
|
EBioMedicine
1 publication, 2.27%
|
|
|
Travel Medicine and Infectious Disease
1 publication, 2.27%
|
|
|
Antiviral Research
1 publication, 2.27%
|
|
|
Life Sciences
1 publication, 2.27%
|
|
|
Biological Reviews
1 publication, 2.27%
|
|
|
Biopolymers
1 publication, 2.27%
|
|
|
Chemical Research in Toxicology
1 publication, 2.27%
|
|
|
Organic Letters
1 publication, 2.27%
|
|
|
Expert Opinion on Investigational Drugs
1 publication, 2.27%
|
|
|
bioRxiv
1 publication, 2.27%
|
|
|
Journal of Antimicrobial Chemotherapy
1 publication, 2.27%
|
|
|
Biochimica et Biophysica Acta - Biomembranes
1 publication, 2.27%
|
|
|
International Journal of Molecular Sciences
1 publication, 2.27%
|
|
|
Protein Science
1 publication, 2.27%
|
|
|
Clinical Pharmacokinetics
1 publication, 2.27%
|
|
|
1
2
3
|
Publishers
|
2
4
6
8
10
12
|
|
|
American Chemical Society (ACS)
11 publications, 25%
|
|
|
Cold Spring Harbor Laboratory
11 publications, 25%
|
|
|
Elsevier
9 publications, 20.45%
|
|
|
Springer Nature
3 publications, 6.82%
|
|
|
Wiley
3 publications, 6.82%
|
|
|
MDPI
2 publications, 4.55%
|
|
|
Frontiers Media S.A.
2 publications, 4.55%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
1 publication, 2.27%
|
|
|
Taylor & Francis
1 publication, 2.27%
|
|
|
Oxford University Press
1 publication, 2.27%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
44
Total citations:
44
Citations from 2024:
7
(15%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Lane T. R. et al. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection // PLoS Neglected Tropical Diseases. 2019. Vol. 13. No. 11. p. e0007890.
GOST all authors (up to 50)
Copy
Lane T. R., Massey C., Comer J. E., Anantpadma M., Freundlich J. S., Davey R. A., Madrid P. B., Ekins S. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection // PLoS Neglected Tropical Diseases. 2019. Vol. 13. No. 11. p. e0007890.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1371/journal.pntd.0007890
UR - https://doi.org/10.1371/journal.pntd.0007890
TI - Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection
T2 - PLoS Neglected Tropical Diseases
AU - Lane, Thomas R
AU - Massey, Christopher
AU - Comer, Jason E.
AU - Anantpadma, Manu
AU - Freundlich, Joel S
AU - Davey, Robert A
AU - Madrid, Peter B
AU - Ekins, Sean
PY - 2019
DA - 2019/11/21
PB - Public Library of Science (PLoS)
SP - e0007890
IS - 11
VL - 13
PMID - 31751347
SN - 1935-2727
SN - 1935-2735
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Lane,
author = {Thomas R Lane and Christopher Massey and Jason E. Comer and Manu Anantpadma and Joel S Freundlich and Robert A Davey and Peter B Madrid and Sean Ekins},
title = {Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection},
journal = {PLoS Neglected Tropical Diseases},
year = {2019},
volume = {13},
publisher = {Public Library of Science (PLoS)},
month = {nov},
url = {https://doi.org/10.1371/journal.pntd.0007890},
number = {11},
pages = {e0007890},
doi = {10.1371/journal.pntd.0007890}
}
Cite this
MLA
Copy
Lane, Thomas R., et al. “Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection.” PLoS Neglected Tropical Diseases, vol. 13, no. 11, Nov. 2019, p. e0007890. https://doi.org/10.1371/journal.pntd.0007890.
Profiles